LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform, aiming to support the growing power demands of artificial intelligence and hyperscale data centers. The company also disclosed that Stuart D. Porter, founder, managing partner, CEO and chief investment officer of Denham Capital Management LP, has joined its board of directors.
LIXTE's new strategy will target power equipment and service solutions for AI data-center campuses, distributed power systems and advanced generation technologies. Simultaneously, the company will seek a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations focused on cancer treatments. The full press release is available at https://ibn.fm/MVXfg.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company that has been focused on new targets for cancer drug development. Its lead compound, LB-100, a first-in-class PP2A inhibitor, has shown tolerability in cancer patients at doses associated with anti-cancer activity. Preclinical data suggest LB-100 could enhance chemotherapies and immunotherapies, improving outcomes for patients. The company's novel approach, termed activation lethality, is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials ongoing for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information is available at www.lixte.com.
Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE has also been pioneering electronically controlled proton therapy systems for treating tumors. The LiGHT System is believed to offer significant advantages over existing proton therapy technologies. Additional details can be found at www.lioratechnologies.com.
This strategic pivot underscores the increasing convergence of biotechnology and energy sectors, driven by the immense power requirements of AI infrastructure. By leveraging Denham Capital's expertise in energy investments, LIXTE aims to capitalize on the growing demand for reliable power solutions. The company's decision to seek a partner for its pharmaceutical operations reflects a broader trend where firms realign core businesses to focus on high-growth opportunities.
The announcement highlights the critical need for innovative energy solutions as AI and data centers expand, potentially reshaping LIXTE's future trajectory. Investors can access the latest updates in the company's newsroom at https://ibn.fm/LIXT.
